{"title":"标准剂量Omalizumab治疗慢性荨麻疹的疗效：一项现实世界研究","authors":"Zijing Xiao, Duoqin Wang, Yanyun Shen, Yixin Shao, Lisi Peng, Taiyu Jin, Yiqi Zhu, Hui Tang","doi":"10.1155/dth/8754260","DOIUrl":null,"url":null,"abstract":"<div>\n <p><b>Background:</b> Omalizumab has been recommended for the treatment of CU. Meanwhile, real-world data are available on the efficacy and safety of omalizumab in patients with CSU, but there is a relative paucity of data on the use of the drug in the treatment of CIndU and CSU combined with CIndU.</p>\n <p><b>Objective:</b> To evaluate the efficacy and safety of omalizumab in Chinese patients with CSU, CholU, SDerm, or both, who had an inadequate response to H1-antihistamine treatment.</p>\n <p><b>Methods:</b> This was an observational, retrospective chart review of patients with CU initiating omalizumab treatment.</p>\n <p><b>Results:</b> In total, 78.4% (<i>n</i> = 80/102) of patients showed a response to omalizumab at the end of the study period, and 36.3% (<i>n</i> = 37/102) showed a complete response. Among patients with different subtypes, 84.8% (<i>n</i> = 38/45) of CSU, 37.5% (<i>n</i> = 3/8) of CholU, 50% (<i>n</i> = 1/2) of SDerm and 80.9% (<i>n</i> = 38/47) of CSU + SDerm comorbidity subgroup patients showed a response. The mean of tIgE levels of responders were significantly higher than nonresponders (649.48 ± 814.69 vs. 264.27 ± 262.49 ng/mL, <i>p</i> = 0.004). Patients with isolated CSU exhibited significantly lower relapse rates compared to the CSU + SDerm comorbidity subgroup (42.9% vs. 57.1%, <i>p</i> = 0.042). In total, 12 patients reinitiated omalizumab treatment after a relapse and all of them showed an early response. The mean response time was 1.33 ± 0.65 months. The response mode was similar with their first treatment.</p>\n <p><b>Conclusion:</b> Omalizumab is effective in difficult-to-treat patients with CSU and CSU + SDerm comorbidity subgroup, but the response rates in patients with isolated CholU or SDerm are unsatisfactory. The mean of tIgE levels of responders were significantly higher than nonresponders at baseline. Patients in the CSU + SDerm comorbidity subgroup demonstrate an elevated risk of relapse. These findings support omalizumab’s role in refractory CSU and comorbid CSU + SDerm, but highlight unmet needs in isolated CIndU subtypes.</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8754260","citationCount":"0","resultStr":"{\"title\":\"Efficacy of Standard-Dose Omalizumab Against Chronic Urticaria: A Real-World Study\",\"authors\":\"Zijing Xiao, Duoqin Wang, Yanyun Shen, Yixin Shao, Lisi Peng, Taiyu Jin, Yiqi Zhu, Hui Tang\",\"doi\":\"10.1155/dth/8754260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><b>Background:</b> Omalizumab has been recommended for the treatment of CU. Meanwhile, real-world data are available on the efficacy and safety of omalizumab in patients with CSU, but there is a relative paucity of data on the use of the drug in the treatment of CIndU and CSU combined with CIndU.</p>\\n <p><b>Objective:</b> To evaluate the efficacy and safety of omalizumab in Chinese patients with CSU, CholU, SDerm, or both, who had an inadequate response to H1-antihistamine treatment.</p>\\n <p><b>Methods:</b> This was an observational, retrospective chart review of patients with CU initiating omalizumab treatment.</p>\\n <p><b>Results:</b> In total, 78.4% (<i>n</i> = 80/102) of patients showed a response to omalizumab at the end of the study period, and 36.3% (<i>n</i> = 37/102) showed a complete response. Among patients with different subtypes, 84.8% (<i>n</i> = 38/45) of CSU, 37.5% (<i>n</i> = 3/8) of CholU, 50% (<i>n</i> = 1/2) of SDerm and 80.9% (<i>n</i> = 38/47) of CSU + SDerm comorbidity subgroup patients showed a response. The mean of tIgE levels of responders were significantly higher than nonresponders (649.48 ± 814.69 vs. 264.27 ± 262.49 ng/mL, <i>p</i> = 0.004). Patients with isolated CSU exhibited significantly lower relapse rates compared to the CSU + SDerm comorbidity subgroup (42.9% vs. 57.1%, <i>p</i> = 0.042). In total, 12 patients reinitiated omalizumab treatment after a relapse and all of them showed an early response. The mean response time was 1.33 ± 0.65 months. The response mode was similar with their first treatment.</p>\\n <p><b>Conclusion:</b> Omalizumab is effective in difficult-to-treat patients with CSU and CSU + SDerm comorbidity subgroup, but the response rates in patients with isolated CholU or SDerm are unsatisfactory. The mean of tIgE levels of responders were significantly higher than nonresponders at baseline. Patients in the CSU + SDerm comorbidity subgroup demonstrate an elevated risk of relapse. These findings support omalizumab’s role in refractory CSU and comorbid CSU + SDerm, but highlight unmet needs in isolated CIndU subtypes.</p>\\n </div>\",\"PeriodicalId\":11045,\"journal\":{\"name\":\"Dermatologic Therapy\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8754260\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/dth/8754260\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/8754260","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Efficacy of Standard-Dose Omalizumab Against Chronic Urticaria: A Real-World Study
Background: Omalizumab has been recommended for the treatment of CU. Meanwhile, real-world data are available on the efficacy and safety of omalizumab in patients with CSU, but there is a relative paucity of data on the use of the drug in the treatment of CIndU and CSU combined with CIndU.
Objective: To evaluate the efficacy and safety of omalizumab in Chinese patients with CSU, CholU, SDerm, or both, who had an inadequate response to H1-antihistamine treatment.
Methods: This was an observational, retrospective chart review of patients with CU initiating omalizumab treatment.
Results: In total, 78.4% (n = 80/102) of patients showed a response to omalizumab at the end of the study period, and 36.3% (n = 37/102) showed a complete response. Among patients with different subtypes, 84.8% (n = 38/45) of CSU, 37.5% (n = 3/8) of CholU, 50% (n = 1/2) of SDerm and 80.9% (n = 38/47) of CSU + SDerm comorbidity subgroup patients showed a response. The mean of tIgE levels of responders were significantly higher than nonresponders (649.48 ± 814.69 vs. 264.27 ± 262.49 ng/mL, p = 0.004). Patients with isolated CSU exhibited significantly lower relapse rates compared to the CSU + SDerm comorbidity subgroup (42.9% vs. 57.1%, p = 0.042). In total, 12 patients reinitiated omalizumab treatment after a relapse and all of them showed an early response. The mean response time was 1.33 ± 0.65 months. The response mode was similar with their first treatment.
Conclusion: Omalizumab is effective in difficult-to-treat patients with CSU and CSU + SDerm comorbidity subgroup, but the response rates in patients with isolated CholU or SDerm are unsatisfactory. The mean of tIgE levels of responders were significantly higher than nonresponders at baseline. Patients in the CSU + SDerm comorbidity subgroup demonstrate an elevated risk of relapse. These findings support omalizumab’s role in refractory CSU and comorbid CSU + SDerm, but highlight unmet needs in isolated CIndU subtypes.
期刊介绍：
Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
